» Articles » PMID: 26295825

Relationship Between Chronic Disturbance of 2,3-diphosphoglycerate Metabolism in Erythrocytes and Alzheimer Disease

Overview
Specialties Neurology
Pharmacology
Date 2015 Aug 22
PMID 26295825
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer disease (AD) is one of the most common neurodegenerative disorders widely occurring among the elderly. The pathogenic mechanisms involved in the development of this disease are still unknown. In AD, in addition to brain, a number of peripheral tissues and cells are affected, including erythrocytes. In this study, we analyzed glycolytic energy metabolism, antioxidant status, glutathione, adenylate and proteolytic systems in erythrocytes from patients with AD and compared with those from age-matched controls and young adult controls. Glycolytic enzymes hexokinase, phosphofructokinase, bisphosphoglycerate mutase and bisphosphoglycerate phosphatase displayed lower activities in agematched controls, and higher activities in AD patients, as compared to those in young adult control subjects. In both aging and AD, oxidative stress is increased in erythrocytes whereas elevated concentrations of hydrogen peroxide and organic hydroperoxides as well as decreased glutathione/glutathione disulfide ratio and glutathione transferase activity can be detected. These oxidative disturbances are also accompanied by reductions in ATP levels, adenine nucleotide pool size and adenylate energy charge. Caspase-3 and calpain activities in age-matched controls and AD patients were about three times those of young adult controls. 2,3-diphosphoglycerate levels were significantly decreased in AD patients. Taken together these data suggest that AD patients are associated with chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes. These defects may play a central role in pathophysiological processes predisposing elderly subjects to dementia.

Citing Articles

Exploring glycolytic enzymes in disease: potential biomarkers and therapeutic targets in neurodegeneration, cancer and parasitic infections.

Rojas-Pirela M, Andrade-Alviarez D, Rojas V, Marcos M, Salete-Granado D, Chacon-Arnaude M Open Biol. 2025; 15(2):240239.

PMID: 39904372 PMC: 11793985. DOI: 10.1098/rsob.240239.


Erythrocytes Functionality in SARS-CoV-2 Infection: Potential Link with Alzheimer's Disease.

Kosenko E, Tikhonova L, Alilova G, Montoliu C Int J Mol Sci. 2023; 24(6).

PMID: 36982809 PMC: 10051442. DOI: 10.3390/ijms24065739.


Red blood cells in type 1 diabetes and multiple sclerosis and technologies to measure their emerging roles.

Geiger M, Hayter E, Martin R, Spence D J Transl Autoimmun. 2022; 5:100161.

PMID: 36039310 PMC: 9418496. DOI: 10.1016/j.jtauto.2022.100161.


Altered central and blood glutathione in Alzheimer's disease and mild cognitive impairment: a meta-analysis.

Chen J, Thiyagarajah M, Song J, Chen C, Herrmann N, Gallagher D Alzheimers Res Ther. 2022; 14(1):23.

PMID: 35123548 PMC: 8818133. DOI: 10.1186/s13195-022-00961-5.


Erythrocyte adenosine A2B receptor prevents cognitive and auditory dysfunction by promoting hypoxic and metabolic reprogramming.

Qiang Q, Manalo J, Sun H, Zhang Y, Song A, Wen A PLoS Biol. 2021; 19(6):e3001239.

PMID: 34138843 PMC: 8211187. DOI: 10.1371/journal.pbio.3001239.